Overview

Pioglitazone in Alzheimer Disease

Status:
Completed

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute on Aging (NIA)

Collaborator:

Takeda Pharmaceuticals North America, Inc.

Treatments:

Pioglitazone